Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System AtrophyGlobeNewsWire • 12/04/24
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International SymposiumGlobeNewsWire • 11/12/24
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434GlobeNewsWire • 11/06/24
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024GlobeNewsWire • 10/14/24
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience MeetingGlobeNewsWire • 10/11/24
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®GlobeNewsWire • 10/02/24
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®GlobeNewsWire • 09/23/24
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 07/17/24
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 07/17/24
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' WebinarGlobeNewsWire • 06/12/24
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History StudyGlobeNewsWire • 05/29/24
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewGlobeNewsWire • 05/08/24
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's AtaxiaGlobeNewsWire • 04/29/24
Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingGlobeNewsWire • 04/17/24
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024GlobeNewsWire • 04/10/24
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundGlobeNewsWire • 03/26/24
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingGlobeNewsWire • 02/20/24
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewGlobeNewsWire • 02/06/24